PEOPLE - Changes at SynCardia Systems:
This article was originally published in Clinica
SynCardia Systems' plans to launch the CardioWest Total Artificial Heart in the US have gone a step further with the appointment of Michael Quinn, chairman and CEO of Cardiogenesis, as vice-chairman of the board. SynCardia chairman and CEO Dr Marvin Slepian said the move addresses the "need for leadership and a profound understanding of the challenges of commercialising advanced cardiovascular therapies". The appointment is part of the company's "necessary restructuring ... as it transitions from a research organisation to a commercially viable company", added the co-founder of the Tucson, Arizona-based company. Cardiogenesis, of Foothill Ranch, California, makes the Holmium: YAG laser and related accessories for transmyocardial revascularisation (TMR) therapy and percutaneous myocardial channelling.
You may also be interested in...
The WHO’s new "living guideline" against remdesivir’s use in hospitalized patients notwithstanding, some key opinion leaders in India see a role for the antiviral, but underscore that COVID-19 is still in its infancy and all repurposed therapies for the disease still have a long way to go. They also see the US remdesivir studies as more robust.
Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things.
A recent Department of Health and Human Services proposal to review regulations every 10 years may mean good things for the device industry, said David Hoffmeister, partner, Wilson Sonsini Goodrich & Rosati.